Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand Pharmaceuticals (NASDAQ: LGND) announced the expiration of its tender offer for Pfenex Inc. (NYSE American: PFNX), where it sought to acquire all outstanding shares at $12.00 each, plus a potential $2.00 contingent payment. Approximately 27.6 million shares, or 80.3% of Pfenex's outstanding shares, were validly tendered. The merger is expected to close on October 1, 2020, after which Pfenex will become a wholly-owned subsidiary, and its stock will cease trading on the NYSE American. Ligand aims to leverage Pfenex's capabilities to enhance its biopharmaceutical portfolio.